Biogen Idec Ma Inc.

Apoxis S.a.

Topotarget Switzerland Sa

Biogen Ma Inc.

Biogen Idcc Ma Inc.

Apotech R&d S.a.

Jurg Tschopp

Pascal Schneider

Jeffrey L Browning

Christine Ambrose

Fabienne MacKay

Jeffrey Thompson

Catherine A Hession

Olivier Gaide

Fabienne Mackay

A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

Methods of modulating immune responses using BCMA polypeptide

Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)

Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.

Pharmaceutical composition comprising EDA-1 Fusion Protein

Methods of screening for a compound that inhibits the interaction between BAFF and BCMA

Treatment of ectodermal dysplasia with EDA1 fusion proteins

Embodiments of the present invention encompass novel receptors of the TNF family. In particular, embodiments of the invention encompass TNF Receptor in the BRAIN (TRAIN) and isolated antibodies that bind to the same. In some embodiments, isolated antibodies that bind to TRAIN are useful in regulating cell differentiation, death, and survival. Other embodiments of the invention encompass pharmaceutical compositions comprising antibodies that bind to human TRAIN.

Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor

Novel receptor in the TNF family: TRAIN-receptor.

TRAIN-R: a cysteine-rich member of the TNF-receptor family

The present invention relates to novel receptors in the TNF family. A novel receptor has been identified, referred to herein as TRAIN. The invention relates to DNA sequences encoding TRAIN receptors. The invention also contemplates recombinant DNAs comprising a sequence encoding TRAIN receptors or fragments thereof, as well as hosts with stably integrated TRAIN-R sequences introduced into their genome, or possessing episomal elements.

Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor family

Methods of treatment by administering an anti-BCMA antibody

The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.

BAFF, inhibitors thereof and their use in the modulation of B-cell response

Growing community of inventors

Epalinges, Switzerland

Jurg Tschopp